Nicholas Investment Partners LP lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 22.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,307 shares of the company's stock after buying an additional 18,424 shares during the period. Nicholas Investment Partners LP owned about 0.08% of Vaxcyte worth $8,211,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the business. Whipplewood Advisors LLC acquired a new stake in Vaxcyte during the fourth quarter valued at $28,000. Smartleaf Asset Management LLC boosted its position in Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares during the last quarter. National Bank of Canada FI acquired a new stake in Vaxcyte during the fourth quarter valued at $41,000. Blue Trust Inc. boosted its position in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after purchasing an additional 371 shares during the last quarter. Finally, Assetmark Inc. boosted its position in Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after purchasing an additional 775 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.
Vaxcyte Stock Performance
Shares of Vaxcyte stock traded up $0.95 during trading on Friday, reaching $31.85. The company's stock had a trading volume of 1,522,478 shares, compared to its average volume of 1,335,764. The business's fifty day moving average price is $42.56 and its 200-day moving average price is $71.95. The firm has a market cap of $4.11 billion, a price-to-earnings ratio of -6.92 and a beta of 1.27. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period last year, the company posted ($0.85) earnings per share. Sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.
Analyst Upgrades and Downgrades
PCVX has been the subject of a number of research reports. Bank of America reduced their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on Vaxcyte in a report on Tuesday, April 22nd. They set an "overweight" rating on the stock. The Goldman Sachs Group cut their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Finally, Needham & Company LLC restated a "buy" rating and set a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $136.50.
Check Out Our Latest Stock Report on PCVX
Insider Transactions at Vaxcyte
In other news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.37. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.10% of the stock is currently owned by corporate insiders.
Vaxcyte Company Profile
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Further Reading
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
